1. Germany Stocks

  2. •

    Health technology

  3. •

    Biotechnology
TME Pharma N.V.

TME Pharma N.V.

0.11
EUR
+0.00
(+1.96%)
7.07MMarket Cap
TME Pharma N.V.
GETTEX:0N6A
(Gettex)

Recent

price

0.11

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
EUR
0.84
1.45
3.5
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-465.13
-542.79
-453.4
-171.41
-182.35
-5.22
-21.74
-14.81
-9.59
-1
-0.16
-0.03
- -
Basic EPS, GAAP
-421.57
-454.74
-380.21
-134.94
-68.1
-26.06
-10.99
-12.7
-7.71
-0.84
-0.13
-0.04
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-210.36
-236.95
-83.6
-118.34
-17.45
-9.54
11.06
4.1
-0.5
-0.01
0.02
-0.02
0.02
Book Value per Share
-213.33
-238.53
-84.07
-118.49
-17.48
-9.57
11.06
4.09
-0.5
-0.01
0.02
-0.02
0.02
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
1
2
7
36
94
65
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-52,624
-33,206.98
-10,130.12
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-14
-16
-11
-5
-11
-1
-10
-14
-15
-7
-6
-3
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-55,192
-37,446.51
-12,948.19
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-3
-1
-3
-3
-3
-2
8
4
-1
- -
2
-2
2
Working Capital
4
6
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
-6
-7
-2
-4
-3
-2
8
5
-1
- -
2
-2
2
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
-236.43
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
1
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
56
94
Market Capitalization
5
7
7

Working Capital

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
2
3
3
Cash, Cash Equivalents & STI
2
3
3
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
3
1
2
Payables & Accruals
- -
- -
- -
ST Debt
1
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-167.78%
-218.69%
-197.83%
Free Cash Flow
-2.6%
7.2%
-26.39%
Net Income, GAAP
96.32%
-13.91%
-42.59%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-1
2024
- -
- -
-0.16
2025
- -
- -
-0.03

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
TME Pharma N.V. (Euronext Growth Paris: ALTME) is a clinical-stage biopharmaceutical company that develops novel therapies targeting the tumor microenvironment for the treatment of aggressive cancers, including glioblastoma and pancreatic cancer. The company offers proprietary Spiegelmer-based product candidates, such as NOX-A12, a CXCL12-inhibiting aptamer designed to enhance immunotherapy and radiotherapy efficacy by mobilizing stem cells and disrupting tumor protection barriers; and NOX-E36 (emapticap pegol), an L-RNA aptamer neutralizing CCL2 chemokines for anti-fibrotic effects in cancer and ophthalmic diseases. These therapies work in combination with standard treatments like chemotherapy, radiotherapy, and immune checkpoint inhibitors to weaken tumor defenses and improve therapeutic outcomes; the company employs approximately 12 people and generates minimal revenue from pharmaceutical activities. TME Pharma N.V., founded in 1997 and formerly known as NOXXON Pharma until its name change in July 2022, maintains headquarters at Max-Dohrn-Strasse 8-10 in Berlin, Germany, with operations centered in Europe. In recent developments, the company announced a partnership with aimed analytics in January 2025 to leverage artificial intelligence for drug discovery and optimization; initiated a strategic restructuring under new CEO Diede van den Ouden, appointed in June 2025, including a shift to an outsourcing model; secured €2.6 million in guaranteed financing in December 2024 and additional €500,000 via bond issue in August 2025 to support transactions around NOX-A12 and NOX-E36; and is pursuing spin-outs, asset sales of subsidiary TME Pharma AG, and out-licensing deals by June 2025.